uti semaglutide and UTI: does GLP-1 therapy increase urinary tract infection risk? GLP-1 Induced UTIs: What Patients

A Rich R&D Pipeline : As companies continue to develop differentiated therapies with added advantages, the eligible patient population will keep growing

While tirzepatide made history as the first dual GIP/GLP-1 receptor agonist to receive FDA approval, retatrutide pushes the pharmacological envelope further with triple receptor agonism that adds glucagon receptor activation

Personalized prevention depends on each stones composition and urine chemistry

But patients are at the heart of the GLP-1 trend, and the Obesity Action Coalition is there to provide support, education and advocacy for those who want to use these medications as part of their weight-loss plan

For small 5-unit doses, a 0.3mL (30-unit) syringe is much easier to read than a 1.0mL syringe